We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Foliglurax Enters Phase II Trial for Treatment of Parkinson's Patients

News   Jul 10, 2017 | Original Story from Prexton Therapeutics

 
Prexton Therapeutic's Parkinson's Drug Candidate, Foliglurax, Enters Phase II Trial
 
 
 

RELATED ARTICLES

Bioengineered Spinal Discs Successfully Implanted into Goats

News

Engineered spinal discs integrated with native discs maintained their structure and showed near-native mechanical properties 2 months after implantation in a goat model, demonstrating feasibility of this approach.

READ MORE

Paralysis Patient Plays Beethoven Using New Computer Interface

News

Three people with paralysis participating in the BrainGate clinical trial, an effort that includes Brown University researchers, chatted with family and friends, shopped online and used other tablet computer applications, all by just thinking about pointing and clicking a mouse.

READ MORE

New Drug Target for Skin Cancer?

News

Loss of a protein called TRIM29 promotes cancer cell invasion in a common type of skin cancer, suggesting a novel diagnostic marker and a possible therapeutic target.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Neuroscience

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE